Impact of Albuminuria-Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials.

Diabetes Obes MetabJul 28, 2026 (epub)
Clinical ResearchEndocrinologyNephrologyCardiologyOpen access

Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the ROTATE trials evaluated the impact of four albuminuria-lowering drugs on cardiovascular-related ceramides in 63 adults with diabetes. Linagliptin was found to significantly reduce ceramide levels, specifically Cer22, Cer24, and Cer24:1, by 22.6%, 25.7%, and 19.6%, respectively, compared to baseline.

Key findings

  • Linagliptin reduced Cer22 levels by 22.6% (95% CI: -33.58; -9.79, p=0.001).
  • Cer24 levels decreased by 25.7% with linagliptin (95% CI: -38.94; -9.69, p=0.003).
  • Cer24:1 levels were reduced by 19.6% (95% CI: -31.34; -5.95, p=0.007) with linagliptin.

Why it matters

Understanding the effects of diabetes treatments on ceramide levels may provide insights into cardiovascular risk management in diabetic patients. This could help clinicians tailor therapies to improve cardiovascular outcomes.

Source

PubMed · PMID 42517687Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.